{
    "nctId": "NCT03623789",
    "officialTitle": "Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal\u00ae Application, a Comparison With Intravenous Tranexamic Acid Only in Total Hip Arthroplasty",
    "inclusionCriteria": "1. Patients with osteoarthritis of the hip secondary to degeneration, inflammatory arthritis, gouty arthritis, acetabular dysplasia or osteonecrosis of the femoral head, and undergoing primary unilateral minimally invasive THA\n2. Age \\> 18 years and \\< 90 years\n3. Failure of medical treatment or rehabilitation.\n4. Hemoglobin \\> 11g/dl,\n5. No use of non-steroid anti-inflammatory agent one week before operation\n* Must have minimum age of 18 Years\n* Must have maximum age of 90 Years",
    "exclusionCriteria": "1. Preoperative Hemoglobin \u226611 g/dl\n2. History of infection or intraarticular fracture of the affective hip\n3. Renal function deficiency (GFR \\<30 ml/min/1.73m2)\n4. Elevated liver enzyme (aspartate transaminase (AST)/ alanine transaminase(ALT) level are more than twice normal range) , history of liver cirrhosis, impaired liver function(elevated total bilirubin level) and coagulopathy (including long-term use anticoagulant)\n5. History of deep vein thrombosis, ischemic heart disease or stroke\n6. Contraindications of tranexamic acid, floseal, or rivaroxaban\n7. Allergy to tranexamic acid, floseal, rivaroxaban, or the excipients\n8. History of heparin-induced thrombocytopenia (HIT)\n9. Coagulopathy or bleeding tendency caused by organ dysfunction, such as cirrhosis, bone marrow suppression etc.\n10. Patient who have active bleeding disorder, such as intracranial hemorrhage, upper gastrointestinal bleeding, hematuria.\n11. Patients with known allergies to materials of bovine origin."
}